TWiV 782: An antibody for all sarbecoviruses

July 22, 2021

On this episode, broadening of immune responses to SARS-CoV-2 after mRNA vaccine booster to ChAdOx1 nCoV-19, five-fold underestimation of the number of cases in the US during the first six months of the pandemic, and a monoclonal antibody that broadly neutralizes many different sarbecoviruses.

Hosts: Vincent Racaniello and Amy Rosenfeld

Click arrow to play
Download TWiV 782 (38 MB .mp3, 63 min)
Subscribe (free): iTunesGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees

Send your virology questions and comments to

Leave a Reply

Your email address will not be published. Required fields are marked *

5 comments on “TWiV 782: An antibody for all sarbecoviruses

  1. Why didn’t we test more people early in the pandemic? Because test kits were scarce.

  2. stan jonas Jul 22, 2021

    Which “Ebola” paper is Amy refering to?


  3. Robert Choy Jul 27, 2021

    Comment on the discussion of the SARS-CoV-2 RBD vaccine candidate that originated at Baylor (from Peter Hotez). Amy mentioned she thought it “didn’t work”. In fact, this candidate is still in development by Biological E (India) and received funding from CEPI at the end of last year:
    It does remain to be seen how this RBD candidate will compare with constructs expressing full-length spike, but given the continuing high demand for vaccines in low- and middle-income countries, it still has the potential to play an important role since CEPI and Biological E are committed to making it available at an affordable price.